Concord Biotech Limited IPO

Mainboard

Pharmaceuticals

Listed On: Aug 18, 2023 at ₹ 900.05(NSE)

₹ 14820 /20 Shares

Check Allotment

Price Summary

Last Closing

1,855.00 (150.34%)

52 Week High

2,664.00

52 Week Low

1,196.25

Last Update

8-Nov-2024 3:30 PM

Concord Biotech Limited IPO Details

04 Aug, 2023

Open Date

08 Aug, 2023

Close Date

11 Aug, 2023

Allotment Date

18 Aug, 2023

Listing Date

Issue Price

₹705-741 per equity share

Face Value

₹1 Per Equity Share

Listing at Group

BSE, NSE

Registrar

Link Intime India Private Limited

List Price

900.05(NSE)

Listing Date

2023-08-18

Market Lot

Retail : 20 Shares (₹14,820/-)
S-HNI : 280 Shares (₹2,07,480/-)
B-HNI : 1,360 Shares (₹10,07,760/-)

Lead Manager

Kotak Mahindra Capital Company Limited
Citigroup Global Markets India Private Limited
Jefferies India Private Limited

Issue Size

Offer for Sale : 20,925,652 shares(aggregating up to ₹1,551.00 Cr)

Retail Portion

35% (Number of Retail Applications: 3,66,024 Approx),
(Number of S-HNI Applications : 3,735 Approx),
(Number of B-HNI Applications : 7,470 Approx)

Subscription

24.86 times

IPO Docs

DRHP RHP ANCHOR

Concord Biotech Limited IPO Subscription Details

As on	QIB	NII bNII sNII	Retail	Employee	Total
Shares Offered / Reserved	4,183,130	3,137,348 2,091,565 1,045,783	7,320,479	10,000	14,650,957
Day 1 - 04-08-23 05:00 PM	0.01 x	1.01 0.96 x 1.11 x	0.72 x	5.73 x	0.58 x
Day 2 - 07-08-23 05:00 PM	1.61 x	5.22 5.12 x 5.42 x	2.26 x	15.68 x	2.72 x
Day 3 - 08-08-23 05:00 PM	67.67 x	16.99 19.30 x 12.36 x	3.77 x	24.39 x	24.86 x

Total No. of Applications: 12,63,516 (Approx)

Retail Subscription on the basis of Applications: 3.45 times

Concord Biotech Limited Valuations

Earnings Per Share (EPS)

₹22.95/-

P/E Ratio

32.3

RoNW

20.06%

Net Asset Value (NAV) - As on 31.03.23

₹123.3

Concord Biotech Limited Company Financials All values are in ₹ Cr.

	31-Mar-23	31-Mar-22	31-Mar-21
Assets	1,513.98	1,312.80	1,182.55
Revenue	888.48	736.35	630.75
Profit After Tax	240.08	174.93	234.89

About The Company

Concord Biotech Limited is an India-based R&D-driven biopharma company. The company is ranked among the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022.

Concord Biotech has a Global presence. They are supplying their products to over 70 countries including the USA, India, Europe, and Japan.

The company manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It started with a single product and has grown to become a wide-spectrum solution provider.

Concord manufactures fermentation and semi-synthetic-based products in therapeutic segments such as Immunosuppressants, Anti-bacterial, Oncology, Antifungals & others. This wide range of products has attracted customers across the globe. Concord also has a robust pipeline of products under development.

	P/B Ratio	P/E Ratio	RoNW	Net Worth
Concord Biotech	6.01	32.3	20.06%	888
Divi's Lab	7.77	54.4	14.9%	7,768
Suven Pharma	7.25	30.6	25.2%	1,340
Laurus Labs	4.49	33.6	20.4%	5,386

Concord Biotech Limited IPO - Ratings

Axis Capital	Neutral
Dilip Davda	May Apply
Choice Equity Broking Pvt Ltd	Subscribe
Reliance Securities	Subscribe
JM Financial Institutional Securities	Neutral

Concord Biotech Limited - Promoter(s)

Pre Issue Share Holding: 44.08%

Post Issue Share Holding: 44.08%

Company Promoter(s)

Mr. Sudhir Vaid
Mr. Ankur Vaid

Concord Biotech Limited IPO - Issue Objectives

Achieve the benefits of listing the Equity Shares on the Stock Exchanges.
Carry out the Offer for Sale of up to 20,925,652 Equity Shares by the Selling Shareholder.

Concord Biotech Limited IPO - Anchor Investors

Concord Biotech raises Rs 465 crore from anchor investors ahead of IPO.

The government of Singapore, Abu Dhabi Investment Authority, Government Pension Fund Global, Polar Capital Funds, HSBC Mutual Fund, WF Asian Reconnaissance Fund, Amundi Funds, The Prudential Assurance Company and Pinebridge Global Funds are the marquee investors that participated in the anchor book of the professionally-managed biotech firm.

Apart from that, Nippon Life, UTI Mutual Fund, DSP Mutual Fund, Franklin Mutual Fund, SBI Life Insurance, Motilal Oswal Mutual Fund, Edelweiss Trusteeship, Invesco India, Bandhan Mutual Fund, Aditya Birla Sun Life, Max Life Insurance and Tata AIA Life Insurance also invested in the company via anchor book.

Concord Biotech Limited IPO - FAQs

Ans. Concord Biotech Limited IPO is a Mainboard IPO. The issue is priced at ₹705-741 per equity share. The minimum order quantity is 20 Shares. The IPO opens on Aug 4, 2023, and closes on Aug 8, 2023. Link Intime India Private Limited is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.

Ans. The Concord Biotech Limited IPO opens on Aug 4, 2023 and closes on Aug 8, 2023.

Ans. The size of Concord Biotech Limited IPO is Offer for Sale : 20,925,652 shares(aggregating up to ₹1,551.00 Cr).

Ans. The IPO price band is set between ₹705-741 per equity share.

Ans. To apply for Concord Biotech Limited IPO IPO, follow the steps given below:

- Open the IPO Ji App or Website
- Find Concord Biotech Limited IPO in the List of IPOs
- Press "Apply" Button
- Select Your Demat Account
- Select Your Shares Quantity and Submit
- Track Your IPO Status

Ans. The share allotment date of Concord Biotech Limited IPO is Aug 11, 2023.

Ans. The Concord Biotech Limited IPO will be listed on Aug 18, 2023.

Ans. Follow the steps to check the allotment status for Concord Biotech Limited IPO here.